Cefmetazole Sodium for Injection

1. Antibacterial effect: (1) Ceftriaxone sodium has high resistance to β-lactamase, so it has strong antibacterial activity against β-lactamase-producing bacteria, which is the same as that against sensitive bacteria that do not produce β-lactamase. (2) It has excellent antibacterial activity against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, indole-negative Proteus, and generally has strong antibacterial activity against indole-positive Proteus that are not sensitive to other cephalosporin and penicillin antibiotics. In addition, it also shows excellent antibacterial activity against anaerobic bacteria such as Bacteroides, Peptococcus and Streptococcus. 2. Mechanism of action: It strongly inhibits the cell wall synthesis of proliferative bacteria and exerts a bactericidal effect. 1. In the subcutaneous administration experiment on young rats, there were reports of testicular atrophy and inhibition of spermatogenesis. 2. When using this agent, it is advisable to regularly check liver function, kidney function and blood. 3. The antigenicity of this product was investigated using mice, rabbits, and guinea pigs. The results were similar to those of other cephalosporin antibiotics. The antigenicity of all animals was weak, and the cross-reactivity with passive skin allergic reactions of cefazolin and cephalothin was also weak. In addition, the Coombs' positive reaction was significantly weaker than that of cephalothin.

Cefmetazole sodium.

This product is white or light to slightly yellow powder.

The following infections caused by bacteria sensitive to this product among Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus (indole-positive and -negative), Bacteroides, Peptococcus and Peptostreptococcus: septicemia; bronchitis, bronchiectasis infection, pneumonia, secondary infection of chronic respiratory diseases, pulmonary suppuration (lung abscess), empyema; cholangitis, cholecystitis; peritonitis; pyelonephritis, cystitis; Bartholinitis, intrauterine infection, adnexitis, parametritis; cellulitis around the jaws, jaw inflammation.

Usually for adults, 1-2 grams (titer) per day, divided into 2 intravenous injections or intravenous drips. Usually for children, 25-100 mg (titer)/kg body weight per day, divided into 2-4 intravenous injections or intravenous drips. In addition, for refractory or severe infections, the daily dose can be increased to 4 grams (titer) for adults and 150 mg (titer)/kg body weight for children according to symptoms, and administered in 2-4 doses. For intravenous injection, 1 gram (titer) of this agent is dissolved in 10 ml of sterile water for injection, normal saline or glucose injection, and injected slowly. In addition, this agent can be added to the rehydration for intravenous drip. When dissolving the intravenous drip agent (100 ml bottle), do not use distilled water for injection (because the solution is not isotonic).

1. Shock (less than 0.01%): Shock may occur (initial symptoms: discomfort, abnormal sensation in the mouth, wheezing, dizziness, urge to defecate, tinnitus, sweating, etc.), so it is necessary to observe carefully. If abnormalities occur, the drug should be discontinued and treated appropriately. 2. Acute renal failure (unknown incidence): Occasionally, severe renal damage such as acute renal failure may occur, so regular examinations should be performed and observations should be observed. If BUN and blood creatinine increase, the drug should be discontinued and treated appropriately. 3. Agranulocytosis (unknown incidence) and hemolytic anemia (unknown incidence): Agranulocytosis and hemolytic anemia may occur, so regular examinations should be performed and observations should be observed. If abnormalities occur, the drug should be discontinued and treated appropriately. 4. Pseudomembranous colitis (less than 0.01%): Occasionally, severe colitis such as pseudomembranous colitis with bloody stools may occur (initial symptoms: abdominal pain, frequent diarrhea), so it is necessary to observe carefully. If abnormalities occur, the drug should be discontinued and treated appropriately. 5. Interstitial pneumonia (unknown incidence) and PIE syndrome (unknown incidence): Interstitial pneumonia and PIE syndrome with fever, cough, dyspnea, abnormal chest X-ray, eosinophilia, etc., if such symptoms occur, the drug should be discontinued immediately and appropriate treatment such as adrenocortical hormone preparations should be given. 6. Other side effects Mucocutaneous eye syndrome: Mucocutaneous eye syndrome (Stenens-Johnson syndrome) has been reported with other cephem antibiotics.

Patients with a history of shock to the ingredients of this drug should not use this drug. Patients with a history of allergy to the ingredients of this drug or cephem antibiotics should use this drug with caution if necessary.

Precautions for combined use (cautions should be taken when combined): 1. Alcohol: Drinking alcohol may cause disulfiram-like effects (facial flushing, palpitations, dizziness, headache, vomiting, etc.). Avoid drinking alcohol during and for at least 1 week after administration. Although the mechanism is unclear, the N-methylthiotetrazolyl group on the 3-position side chain may have a disulfiram-like effect. 2. Diuretics (furosemide, etc.): They may enhance renal damage. Although the mechanism is unknown, it has been reported that in animal experiments (rats), combined use of furosemide has resulted in mild to moderate nuclear atrophy and condensation of proximal renal tubular epithelial cells.

Store at room temperature.

2.0g (calculated as C15H17N7O5S3)

Hainan Tianhuang Pharmaceutical Co., Ltd.

• Founded in:

  2003-05-06

• Address:

  No. 6, Airport North Road, Jiangdong New District, Meilan District, Haikou City

• Tax NO.:

  91460000747766856B

• Registered Funds:

  35.5114 million yuan

• Email:

  Log in to view